Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,672 stopped studies mapped to Malignant Reproductive System Neoplasm and descendants · 89% state a reason
Over the 1,672 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03323398 | Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in… | Phase 1 / Phase 2 | terminated | Oct 27, 2017 | ModernaTX, Inc. | This study was halted prematurely because the efficacy endpoints were not met for either treatment… | Efficacy / futility |
| NCT04293406 | pCHIP: Prostate Cancer Health Impact Program | — | terminated | Mar 3, 2020 | Weill Medical College of Cornell University | Study has been stopped due to lack of follow up questionnaires being completed. | Other (stated, no rule matched) |
| NCT04628780 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 16, 2020 | Pfizer | Pfizer has made an internal business decision to not continue further development of PF-07209960.… | Safety / toxicity |
| NCT04408599 | A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid… | Phase 1 / Phase 2 | terminated | May 29, 2020 | NextCure, Inc. | Upon completion of the Phase 1 portion of the NC410 monotherapy trial, NextCure focused efforts on… | Other (stated, no rule matched) |
| NCT03134027 | Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of…(Immune PDX) | — | terminated | Apr 28, 2017 | Duke University | Poor accrual | Enrollment / accrual |
| NCT04159896 | ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer | Phase 2 | terminated | Nov 12, 2019 | Barbara Ann Karmanos Cancer Institute | The study was closed to accrual on 3/1/21 due to safety concerns since 2 patients experienced CVA… | Safety / toxicity |
| NCT03439085 | DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and… | Phase 2 | terminated | Feb 20, 2018 | M.D. Anderson Cancer Center | Project delays | Other (stated, no rule matched) |
| NCT03770455 | Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC | Phase 2 | terminated | Dec 10, 2018 | Jodi Layton, MD | Early signs of progression and learned experience that the assumed time period between psa… | Other (stated, no rule matched) |
| NCT03690141 | An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced… | Phase 2 | terminated | Oct 1, 2018 | Effector Therapeutics | Terminated early due to a lack of efficacy. | Efficacy / futility |
| NCT03367871 | Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer | Phase 2 | terminated | Dec 11, 2017 | University of Miami | Investigator left institution | Investigator |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2018 | ADC Therapeutics S.A. | Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity.… | Other (stated, no rule matched) |
| NCT03632655 | A Prospective, Randomized Trial Comparing Office-based MR-guided Prostate Biopsy… | N/A | terminated | Aug 15, 2018 | Weill Medical College of Cornell University | The study was terminated due to procurement of new funding sources. | Funding |
| NCT01794936 | Pilot Study of VTI Doppler Probe Use to Identify Neurovascular Bundle During Prostate… | N/A | terminated | Feb 20, 2013 | Columbia University | PI left the institution | Investigator |
| NCT03458234 | RAD 1801: Pilot Study of Intra-Urethral Radiotransponder Beacon Guided Focal Prostate…(RAD1801) | N/A | terminated | Mar 8, 2018 | University of Alabama at Birmingham | No longer manufacturing radiotransponder beacons. No similar product available. The results are no… | Drug supply |
| NCT04004884 | Liver Safety Assessment During Ulipristal Acetate Treatment for Uterine Fibroids (LISA)(LISA) | — | terminated | Jul 2, 2019 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Lack of recruitment | Enrollment / accrual |
| NCT04726332 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors… | Phase 1 | terminated | Jan 27, 2021 | Exelixis | Business reasons | Sponsor / business decision |
| NCT03035357 | Neoadjuvant Listeria or Daratumumab in Prostate Cancer | Phase 2 | withdrawn | Jan 30, 2017 | M.D. Anderson Cancer Center | PI's Request | Other (stated, no rule matched) |
| NCT05107739 | A Study of DeTIL-0255 in Adults With Advanced Malignancies | Phase 1 | terminated | Nov 4, 2021 | Nurix Therapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04684628 | 68Ga-PSMA PET/CT in Prostate Cancer | Phase 3 | suspended | Dec 24, 2020 | University of Saskatchewan | Study is suspended due to some logistic issues | Other (stated, no rule matched) |
| NCT05807126 | Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP… | Phase 1 | withdrawn | Apr 11, 2023 | National Cancer Institute (NCI) | No subjects enrolled in the study | Enrollment / accrual |
| NCT06046274 | GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial… | Phase 2 | withdrawn | Sep 21, 2023 | Genmab | Enrollment challenged by availability of other treatment options | Enrollment / accrual |
| NCT04927559 | Health Literacy in Understanding Radiation Therapy Information in Patients Undergoing… | — | terminated | Jun 16, 2021 | University of Southern California | Low accrual | Enrollment / accrual |
| NCT04458311 | Abiraterone Acetate in Combination With Tildrakizumab(ACTIon) | Phase 1 / Phase 2 | terminated | Jul 7, 2020 | Institute of Cancer Research, United Kingdom | Funder decided that response outcomes to date did not support continuation of the study. | Other (stated, no rule matched) |
| NCT04542603 | Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of… | Phase 1 | withdrawn | Sep 9, 2020 | University of Alabama at Birmingham | No recruitment/enrollment and funding expired. | Enrollment / accrual |
| NCT05538624 | A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma… | Phase 1 / Phase 2 | terminated | Sep 14, 2022 | Avenge Bio, Inc | Sponsor Decision to close study | Sponsor / business decision |
| NCT04633148 | Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients… | Phase 1 | terminated | Nov 18, 2020 | AvenCell Europe GmbH | Although IMP has been well tolerated, biological activity was very limited. The sponsor concluded… | Other (stated, no rule matched) |
| NCT01393119 | Phase II, Dose Finding Study of GTx-758 | Phase 2 | terminated | Jul 13, 2011 | GTx | FDA Clinical Hold | Other (stated, no rule matched) |
| NCT03128294 | Long Term Survivors in Ovarian Cancer | — | terminated | Apr 25, 2017 | University Medical Center Groningen | Data was not sufficiently complete and reliable for analysis (retrospective chart research) | Other (stated, no rule matched) |
| NCT05877404 | Practice Patterns Among Gynecologic Oncologists on Tumor Genetic Testing in Endometrial… | — | terminated | May 26, 2023 | Wake Forest University Health Sciences | This was a national survey of physicians. Per the protocol, they were only allowed to be contacted… | Other (stated, no rule matched) |
| NCT03311334 | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in… | Phase 1 / Phase 2 | terminated | Oct 17, 2017 | Sumitomo Pharma America, Inc. | Sponsor's decision to terminate development of the program. | Sponsor / business decision |
| NCT04731441 | Exercise Intervention Prior to CRS-HIPEC: Feasibility & Impact | N/A | terminated | Feb 1, 2021 | Milton S. Hershey Medical Center | Difficulty enrolling and we lost exercise specialist | Enrollment / accrual |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | Phase 1 | terminated | Sep 29, 2021 | Pfizer | The study was terminated by the Sponsor due to business decision and not due to any safety concerns… | Safety / toxicity |
| NCT04677855 | Study of PCUR-101 in Combination With ADT in Patients With mCRPC | Phase 1 | terminated | Dec 21, 2020 | Pellficure Pharmaceuticals, Inc | Business Decision due to insufficient enrollment | Enrollment / accrual |
| NCT03810105 | A Study of Olaparib and Durvalumab in Prostate Cancer | Phase 2 | terminated | Jan 18, 2019 | Memorial Sloan Kettering Cancer Center | Due to low accrual | Enrollment / accrual |
| NCT06355843 | Clinical Applications of Integrated PET/MR and PET/CT in the Diagnosis and Treatment of… | N/A | suspended | Apr 9, 2024 | The First Affiliated Hospital of Anhui Medical University | The 68Ge/68Ga generator is currently at the end of its lifespan. We are trying to purchase new… | Other (stated, no rule matched) |
| NCT05390021 | PET/MRI in Endometrial Cancer | N/A | withdrawn | May 25, 2022 | Massachusetts General Hospital | Unable to enroll patients to study | Enrollment / accrual |
| NCT05445882 | N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for… | Phase 2 | withdrawn | Jul 6, 2022 | National Cancer Institute (NCI) | Closed by study team, no subjects enrolled. | Enrollment / accrual |
| NCT04743999 | Evaluation of Outcomes in Women Undergoing Multimodality Treatment for Advanced Stage… | Phase 2 | terminated | Feb 8, 2021 | Henry Ford Health System | Low accrual | Enrollment / accrual |
| NCT05033132 | A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in… | Phase 2 | withdrawn | Sep 2, 2021 | Agenus Inc. | Study was never initiated. | Other (stated, no rule matched) |
| NCT00889733 | Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer(OVHM-01) | Phase 1 / Phase 2 | terminated | Apr 29, 2009 | University Health Network, Toronto | Poor recruitment | Enrollment / accrual |
| NCT01962948 | Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or… | Phase 1 / Phase 2 | terminated | Oct 16, 2013 | Fox Chase Cancer Center | Study drug is no longer supplied by grantor. | Other (stated, no rule matched) |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With… | Phase 1 | terminated | Dec 23, 2020 | Ikena Oncology | Sponsor business decision. | Sponsor / business decision |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | Phase 1 | terminated | Dec 31, 2020 | Ikena Oncology | Sponsor business decision. | Sponsor / business decision |
| NCT04243941 | PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer | Phase 2 | withdrawn | Jan 28, 2020 | UNC Lineberger Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT04586335 | Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With… | Phase 1 | terminated | Oct 14, 2020 | Haihe Biopharma Co., Ltd. | Business decision | Sponsor / business decision |
| NCT03657108 | CivaSheet With Radical Prostatectomy & Adjuvant External Beam Radiation | N/A | terminated | Sep 4, 2018 | Icahn School of Medicine at Mount Sinai | Decision made by DSMB to terminate study in April 2023. | Other (stated, no rule matched) |
| NCT03909893 | A Study of Adaptive Radiation Therapy for Pelvic Genitourinary Cancer(ARTGU) | N/A | withdrawn | Apr 10, 2019 | University Health Network, Toronto | This study is being closed. The protocol may be reviewed and consolidated under a new study… | Other (stated, no rule matched) |
| NCT02574442 | Pilot Study In Vivo Confocal Microscopy Probe for Cervical Precancer(Confocal) | — | terminated | Oct 12, 2015 | British Columbia Cancer Agency | Funding has run out | Funding |
| NCT03285841 | OCT-AF Imaging of Pre-cancers of Vulva and Cervix | — | terminated | Sep 18, 2017 | British Columbia Cancer Agency | No funding | Funding |
| NCT05361915 | Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration… | Phase 2 | suspended | May 5, 2022 | Sorrento Therapeutics, Inc. | Sorrento Therapeutics filed for chapter 11 bankruptcy. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 31, 2024source: clinicaltrials